Preliminary Figures for the first half of 2022
Formycon has recently announced its preliminary and unaudited financial results…
EU Approval for FYB201
We are very excited about the EU approval of FYB201, the third major milestone…
Prescriptions of biosimilars in 2021 increase to two-thirds
The share of biosimilars in daily therapy doses continued to rise last year.…
Positive Phase III Study Results for FYB202
The Phase III clinical trial for Formycon's biosimilar ustekinumab candidate…
Great job Formycon Beachvolleyball-Group #RanibizuNET!
Established just a few weeks ago and already competing at the…
FYB207 Projektupdate auf dem 3. Forum Science & Health
Das 3. Forum Science & Health, organisert von BioM im Auftrag des…
Formycon ist innovativ durch Forschung
Mit der Mission, durch unsere Biosimilars mehr Patienten Zugang zu hochwertigen…